The inhibitory effect of DEX in cerebral ischemia-induced TRPM2 and TRPV1 activation should be considered a potential pharmacological target for itching caused by cerebral ischemia-mediated activation of pain and brain injuries. This evidence concerns the gene TRPM2 and brain injury.